Biopharmaceutical firm Altimmune has partnered with the University of Alabama at Birmingham (UAB) to develop a Covid-19 vaccine for intranasal administration.
AdCOVID, the vaccine candidate, will be a single-dose formulation. Altimmune has already created the candidate and is working towards immunogenicity studies.
The company is also preparing to produce Phase I clinical trial material.